XBiotech (XBIT) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free XBIT Stock Alerts $8.13 -0.08 (-0.97%) (As of 12:16 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineXBiotech (NASDAQ:XBIT) Stock Price Crosses Above 50 Day Moving Average of $7.45americanbankingnews.com - April 26 at 4:30 AMXBiotech Inc. (XBIT) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com - April 25 at 9:18 PMXBiotech Incmoney.usnews.com - April 24 at 10:40 AMXBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $7.19americanbankingnews.com - April 18 at 4:06 AMXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insidersfinance.yahoo.com - March 20 at 5:09 AMXBIT Stock Earnings: XBiotech Reported Results for Q4 2023investorplace.com - March 18 at 5:07 PMXBiotech Inc. (NASDAQ:XBIT) Short Interest Up 35.4% in Februarymarketbeat.com - March 14 at 7:22 AMThe Zacks Analyst Blog Highlights Quince Therapeutics and XBiotechfinance.yahoo.com - March 8 at 10:02 AMXBIT Mar 2024 5.000 callfinance.yahoo.com - February 17 at 2:32 AMXBiotech (NASDAQ:XBIT) Shares Cross Above 50 Day Moving Average of $4.56marketbeat.com - February 15 at 4:15 AMXBiotech Inc. (NASDAQ:XBIT) Short Interest Updatemarketbeat.com - February 15 at 1:58 AMXBiotech (NASDAQ:XBIT) Stock Price Passes Above Fifty Day Moving Average of $4.37marketbeat.com - February 7 at 9:19 AMXBiotech (NASDAQ:XBIT) Research Coverage Started at StockNews.commarketbeat.com - February 7 at 4:12 AMXBiotech Inc XBITmorningstar.com - January 18 at 8:23 PMA top Austin biopharmaceutical company is doubling down on its Austin campusbizjournals.com - January 8 at 6:40 PMXBiotech to Begin Constructing New R&D Facility on its 48-acre Campusfinance.yahoo.com - January 4 at 9:17 AMARCT, EHTH and CRTO are among after hour moversmsn.com - December 15 at 10:31 PMCompanies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growthfinance.yahoo.com - December 5 at 2:57 PMXBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritisfinanznachrichten.de - November 14 at 10:14 AMDr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritisfinance.yahoo.com - November 14 at 10:14 AMXBiotech Inc. (NASDAQ:XBIT) Short Interest Up 72.4% in Septembermarketbeat.com - September 28 at 6:18 AMXBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Strokefinance.yahoo.com - September 26 at 12:31 PMXBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trialfinanznachrichten.de - August 8 at 12:23 PMXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trialfinance.yahoo.com - August 8 at 12:23 PMXBiotech Cancer Drug Survival Claim Falls Apart Under Scrutinythestreet.com - June 30 at 8:58 AMStockNews.com Initiates Coverage on XBiotech (NASDAQ:XBIT)marketbeat.com - June 2 at 1:27 AMXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patientsfinanznachrichten.de - May 23 at 8:48 PMFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patientsfinance.yahoo.com - May 22 at 1:26 PMXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Sharesfinanznachrichten.de - May 17 at 9:50 AMXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Sharesfinance.yahoo.com - May 17 at 9:50 AMXBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Strokefinanznachrichten.de - April 17 at 2:39 PMXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Strokefinance.yahoo.com - April 17 at 9:38 AMXBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insidersfinance.yahoo.com - April 9 at 12:31 PMXBiotech (NASDAQ:XBIT) Earns Hold Rating from Analysts at StockNews.commarketbeat.com - April 4 at 1:25 AMThe past three years for XBiotech (NASDAQ:XBIT) investors has not been profitablefinance.yahoo.com - February 15 at 10:06 AMXBiotech (NASDAQ:XBIT) Cut to Sell at StockNews.commarketbeat.com - November 15 at 3:13 AMShort Interest in XBiotech Inc. (NASDAQ:XBIT) Grows By 42.4%marketbeat.com - November 12 at 6:48 AMXBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)finance.yahoo.com - November 11 at 7:50 AMInsiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the companyfinance.yahoo.com - October 31 at 12:05 PMHelicobacter pylori Infection Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2022-2032) | DelveInsight - PR Newswireprnewswire.com - October 18 at 4:21 PMXBiotech (NASDAQ:XBIT) Lowered to "Sell" at StockNews.commarketbeat.com - October 18 at 2:17 AMXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - Yahoo Financefinance.yahoo.com - October 13 at 5:53 PMXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - GlobeNewswireglobenewswire.com - October 13 at 12:52 PMXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancerfinance.yahoo.com - October 13 at 12:52 PMXBiotech Inc. (NASDAQ:XBIT) Short Interest Down 22.2% in Septembermarketbeat.com - September 29 at 3:58 AMXBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year agofinance.yahoo.com - September 8 at 10:50 AMStockNews.com Lowers XBiotech (NASDAQ:XBIT) to Sellmarketbeat.com - September 2 at 11:08 PMWe Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Nasdaqnasdaq.com - September 2 at 4:27 PMShort Interest in XBiotech Inc. (NASDAQ:XBIT) Increases By 89.5%marketbeat.com - August 26 at 2:42 AMWe Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Yahoo Financefinance.yahoo.com - August 14 at 10:26 PM Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide XBIT Media Mentions By Week XBIT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XBIT News Sentiment▼0.000.33▲Average Medical News Sentiment XBIT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XBIT Articles This Week▼30▲XBIT Articles Average Week Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PYXS News Today NKTR News Today PRLD News Today VSTM News Today KMDA News Today AQST News Today RAPT News Today XOMA News Today AEON News Today NBTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XBIT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
